Loading insider details...
Latest Form 4 (Nov 5, 2026): Purchase of 2,321,262 LYEL shares, $25.00M.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Nov 5, 2026 | Lyell Immunopharma, Inc. (LYEL) | Purchase | 2,321,262 | $25.00M |
| Nov 3, 2026 | Aspen Neuroscience, Inc. (ASPE) | Purchase | 1,200,000 | $18.00M |
| Aug 21, 2026 | Neumora Therapeutics, Inc. (NMRA) | Grant/Award | 500,000 | n/a |
| Jun 24, 2026 | Kardigan, Inc. (KARD) | Purchase | 1,250,000 | $20.00M |
| Jun 22, 2026 | Kardigan, Inc. (KARD) | Conversion | 13,792,035 | n/a |
| Mar 9, 2026 | Lyell Immunopharma, Inc. (LYEL) | Purchase | 488,090 | $12.50M |
| Feb 19, 2026 | Neumora Therapeutics, Inc. (NMRA) | Sale | 9,819 | $34.5K |
| Jan 9, 2026 | Neumora Therapeutics, Inc. (NMRA) | Grant/Award | 1,650,000 | n/a |
| May 30, 2025 | Neumora Therapeutics, Inc. (NMRA) | Disposition to Issuer | 497,049 | n/a |
| Feb 20, 2025 | Neumora Therapeutics, Inc. (NMRA) | Sale | 13,871 | $23.5K |